Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nanrilkefusp alfa + pembrolizumab in advanced solid tumors
NCT05256381Phase 2Terminated
- Sponsor
- SOTIO Biotech
- Start
- Jun 2022
- Primary completion
- Aug 2024
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Fc-Fusion Proteins
- Countries
- 9
01
Overview
A Phase 2 trial of nanrilkefusp alfa in non-small cell lung cancer (NSCLC), colorectal cancer (CRC), cutaneous squamous cell carcinoma (cSCC), hepatocellular carcinoma (HCC), castration-resistant prostate cancer (CRPC), sponsored by SOTIO Biotech. Started Jun 2022; status: terminated.
02
Drugs
nanrilkefusp alfa
03
Conditions
non-small cell lung cancer (NSCLC)colorectal cancer (CRC)cutaneous squamous cell carcinoma (cSCC)hepatocellular carcinoma (HCC)castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT05256381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05256381.